Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer (DISC)
Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer
Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
This PHASE2 trial investigates Breast Neoplasm Female and Metastatic Breast Cancer and is currently actively recruiting participants. The Institute of Molecular and Translational Medicine, Czech Republic leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Aug 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Dec 2018 — Feb 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Institute of Molecular and Translational Medicine, Czech Republic
- University Hospital Olomouc
For direct contact, visit the study record on ClinicalTrials.gov .